Articles

AST SpaceMobile’s stock resumes rally as first commercial satellite launch nears

Space-based broadband company AST SpaceMobile is planning the launch of its first five commercial satellites on or after Sept. 12.

Here’s why airline stocks merit another look, analyst says

Demand is starting to pick up and exceed capacity, brightening fall prospects for U.S. airlines.

S&P 500 just saw its worst first week of September since 1953, this chart shows

The S&P 500 index just had a particularly ugly start to September in a historically rough month for the U.S. stock market, according to Bespoke Investment Group.

How to pursue high income with relative safety while diversifying your portfolio

These high-yield bond funds have high ratings for long-term returns.

Bond traders believe the Fed has waited too long to cut interest rates, according to this indicator

A long-awaited shift in the relationship between the 2-year and 10-year Treasury notes wasn’t the only recession warning to emerge from the bond market on Friday.

Cannabis stocks rally after Trump supports moving drug to less restrictive category

GOP presidential nominee Donald Trump supports Schedule III classification for cannabis, which has already been proposed by the Biden administration.

Boeing’s stock bounces as agreement with machinists union removes a headwind

Boeing’s stock was headed for a nice bounce Monday, as the tentative agreement reached with the International Association of Machinists District 751 removed one of the headwinds the aerospace giant has been facing.

Nvidia’s stock has been a huge S&P 500 driver. Here’s why its influence could wane.

With more Nvidia earnings growth ahead, Citi says the company should still help the S&P 500’s performance, though potentially not to the same extent as before.

Stick to defensive stocks as short-term yields dive, say JPMorgan strategists

JPMorgan now favors small caps over large caps, and no longer likes growth over value

‘I’ve never invested in the stock market’: I’m 64 with $400,000 in CDs and a high-yield savings account. Should I invest in bonds?

“Interest rates are going down so CDs might not be an option for long.”

Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck’s blockbuster Keytruda.

KeyCorp to book $700 million loss on sale of securities

The transaction marks an example of efforts by financial firms to reposition their balance sheets with higher-yielding assets as interest rates have risen.
1 437 438 439 440 441 1,957